Fenofibrate Capsules 200 mg Recalled for CGMP Manufacturing Deviations
Ajanta Pharma USA Inc. is recalling Fenofibrate Capsules, USP 200 mg due to Current Good Manufacturing Practice (CGMP) deviations identified during production. The recall affects 3,648 bottles distributed nationwide.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The FDA classified this as a Class II recall with CGMP deviations cited as the reason. The source text does not report any illnesses, injuries, or hospitalizations. CGMP deviations are manufacturing compliance issues that represent potential but not confirmed safety risks, warranting a Moderate classification per the rubric for low-risk contamination and precautionary recalls.
Plain-English summary
Ajanta Pharma USA Inc., located in Bridgewater, New Jersey, is voluntarily recalling Fenofibrate Capsules, USP 200 mg (100 capsule bottles). The recall was initiated on May 28, 2026, in response to Current Good Manufacturing Practice (CGMP) deviations discovered in manufacturing.
The affected product is identified by Lot # PA02216 with an expiration date of 12/2029. Approximately 3,648 bottles have been distributed nationwide under NDC 27241-120-04.
Consumers taking this medication should contact their healthcare provider or pharmacist about their treatment options. Do not abruptly stop taking prescribed fenofibrate without consulting a healthcare provider, as doing so may affect your medical condition.
The recalled product
- Product
- FENOFIBRATE (FENOFIBRATE)
- Brand
- FENOFIBRATE
- Manufacturer
- Ajanta Pharma USA Inc
- Affected units
- 3,648
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot # PA02216
- Exp. 12/2029
UPCs (3)
- 0327241119040
- 0327241118043
- 0327241120046
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · FENOFIBRATE
- ModerateFenofibrate Capsules Recalled for CGMP Manufacturing Deviations
FDA (Drugs) · 2025-04-16
- ModerateCardinal Health Recalls Fenofibrate Capsules Due to Temperature Excursions
FDA (Drugs) · 2021-06-02
- ModerateFenofibrate Tablets Recalled Due to Foreign Valacyclovir Tablet Presence
FDA (Drugs) · 2018-10-03
Same manufacturer · Ajanta Pharma USA Inc
See all →- HighAripiprazole 30mg bottle contained voriconazole 50mg tablets instead
FDA (Drugs) · 2026-06-24
Same hazard · cgmp deviation
See all →- SevereZicam Cold Remedy Nasal Swabs Recalled for Microbiological Testing Failures
FDA (Drugs) · 2026-09-02
- ModerateGolden State Medical Supply Recalls Carbamazepine Tablets Due to CGMP Deviations
FDA (Drugs) · 2026-08-26
- SevereShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- ModerateShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- HighShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19